Article and Video CATEGORIES

Cancer Journey

Search By

Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University

Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute

Lung Cancer Video Library - First Line Combinations, Immunotherapy with Chemo
Author
Luis Raez, MD FACP FCCP
 

We welcome Dr. Luis Raez, MD FACP FCCP with 2017 updates to our Lung Cancer Video Library.  In this recent video for GRACE, Dr. Raez discusses First Line Combinations, Immunotherapy with Chemotherapy.


 

 

 Dr. Luis Raez, MD FACP FCCP

Chief of Hematology/Oncology and Medical Director, Memorial Cancer Institute
Clinical Associate Professor of Medicine, Florida International University
 

The FDA recently approved Pembrolizumab in combination with chemotherapy for new patients with stage IV or metastatic non-small cell lung cancer.  This important breakthrough is based on a small study, a randomized phase II study, presented by Merck that basically shows that there is a benefit of adding the immunotherapy agent Pembrolizumab to the conventional chemotherapy carboplatin base.  This is very important because, until three weeks ago, the only way a patient could get immunotherapy in the front line was if he was able to have the PD-L1 marker expression in the tumor more than 50%.  So that was the only approval for immunotherapy as a single agent for new patients.  Since the approval now, the patient not only can have Pembrolizumab but can also have chemotherapy at the same time with the idea to improve response rate and progression-free survival.  So this is a very important landmark approval but it is not based on a phase III randomized study so this approval has to be verified as a condition to a phase III study that is ongoing that needs to be finished and the results presented to see if this combination of Pembrolizumab with chemotherapy is going to be our new standard of care.  That is why it is not embraced by all the doctors yet.  The other important thing to remember is that, in this approval given by the FDA, patients do not have to the 50% staining of their tumors with the marker PD-L1. If you will remember, I said at the beginning, if you want to have Pembrolizumab as a single agent as a new patient, you have to stain more than 50% of your tumor with the PD-L1.  If you are going to use now  Pembrolizumab with chemotherapy we don’t need the stain.  It is approved now for people that have a higher stain of more than 50% and for people who have less stain, less the 49 or 50%.  That is a very important difference.  The other thing is we already have six other immunotherapy agents in development, at least, and we have a lot of expectation waiting to know what is going to happen with the other immunotherapy agents and, hopefully, some of them will be able to be more in the front line. 


  

Next Previous link

Previous PostNext Post

Related Content

Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Yang, Das, and Dagogo-Jack discuss commonly used terms in treatment options for lung cancer, how oncologists determine the stage of lung cancer, and what that means for treatment, the importance of driver mutation in NSCLC treatment, the vast number of NSCLC trials, among other topics which involve lung cancer treatments. To watch the complete playlist click here.
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Jeff Yang, discusses different surgical procedures used to treat early-stage lung cancer and different approaches to removing cancerous tissue from the lung. 
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Millie Das, discusses different Studies and Trials for NSCLC. Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is the Chief of Oncology at the Palo Alto VA and is an active member of the VA National Lung Cancer Working Group and Lung Cancer Precision Oncology Program. Learn more about Dr. Das here.

Forum Discussions

Hi and welcome to Grace.  Wow, I don't know why you can't get in to see your doc but I'd find a way or find another doc who can walk you...

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Recent Comments

JOIN THE CONVERSATION
 Hi arm2966, Welcome to…
By JanineT GRACE … on
Joanne indwelling catheters
By arm2966 on
Hi and welcome to Grace. …
By JanineT GRACE … on
Hi Amber, Welcome to Grace. …
By JanineT GRACE … on